[go: up one dir, main page]

NO20082559L - Humane monoklonale antistoffer mot protein tyrosin kinase 7 (PTK7) og fremgangsmater for anvendelse av anti-PTK7 antistoffer - Google Patents

Humane monoklonale antistoffer mot protein tyrosin kinase 7 (PTK7) og fremgangsmater for anvendelse av anti-PTK7 antistoffer

Info

Publication number
NO20082559L
NO20082559L NO20082559A NO20082559A NO20082559L NO 20082559 L NO20082559 L NO 20082559L NO 20082559 A NO20082559 A NO 20082559A NO 20082559 A NO20082559 A NO 20082559A NO 20082559 L NO20082559 L NO 20082559L
Authority
NO
Norway
Prior art keywords
ptk7
antibodies
methods
monoclonal antibodies
human monoclonal
Prior art date
Application number
NO20082559A
Other languages
English (en)
Norwegian (no)
Inventor
Chin Pan
Jonathan Alexander Terrett
Li-Sheng Lu
Original Assignee
Medarex Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38123515&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20082559(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medarex Llc filed Critical Medarex Llc
Publication of NO20082559L publication Critical patent/NO20082559L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO20082559A 2005-12-08 2008-06-02 Humane monoklonale antistoffer mot protein tyrosin kinase 7 (PTK7) og fremgangsmater for anvendelse av anti-PTK7 antistoffer NO20082559L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74837305P 2005-12-08 2005-12-08
PCT/US2006/046837 WO2007067730A2 (en) 2005-12-08 2006-12-08 Human monoclonal antibodies to protein tyrosine kinase 7 ( ptk7 ) and their use

Publications (1)

Publication Number Publication Date
NO20082559L true NO20082559L (no) 2008-07-07

Family

ID=38123515

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082559A NO20082559L (no) 2005-12-08 2008-06-02 Humane monoklonale antistoffer mot protein tyrosin kinase 7 (PTK7) og fremgangsmater for anvendelse av anti-PTK7 antistoffer

Country Status (21)

Country Link
US (3) US8222375B2 (me)
EP (1) EP1957539B1 (me)
JP (1) JP5401639B2 (me)
KR (1) KR101373464B1 (me)
CN (1) CN101360761B (me)
AU (1) AU2006321841C1 (me)
BR (1) BRPI0619582A2 (me)
CA (1) CA2632552C (me)
DK (1) DK1957539T3 (me)
EA (1) EA017812B1 (me)
ES (1) ES2406063T3 (me)
IL (1) IL191788A (me)
ME (1) ME02002B (me)
NO (1) NO20082559L (me)
NZ (2) NZ569236A (me)
PL (1) PL1957539T3 (me)
PT (1) PT1957539E (me)
RS (1) RS52804B (me)
SG (1) SG177194A1 (me)
SI (1) SI1957539T1 (me)
WO (1) WO2007067730A2 (me)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101360761B (zh) 2005-12-08 2012-09-12 米德列斯公司 抗蛋白质酪氨酸激酶7（ptk7）的人单克隆抗体及其用途
NZ568015A (en) * 2005-12-08 2012-03-30 Medarex Inc Human monoclonal antibodies to O8E
EP2185188B1 (en) 2007-08-22 2014-08-06 Medarex, L.L.C. Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions
US7960125B2 (en) * 2007-09-25 2011-06-14 The Board Of Trustees Of The Leland Stanford Junior University Identification of thymically derived CD4 T cells by protein tyrosine kinase 7 expression
SG187482A1 (en) * 2007-11-07 2013-02-28 Celldex Therapeutics Inc Antibodies that bind human dendritic and epithelial cell 205 (dec-205)
EP2229187A2 (en) * 2007-11-30 2010-09-22 Bristol-Myers Squibb Company Monoclonal antibody partner molecule conjugates directed to protein tyrosine kinase 7 (ptk7)
WO2009116764A2 (ko) * 2008-03-17 2009-09-24 연세대학교 산학협력단 Ptk7 단백질의 기능 저해를 통한 세포의 이동, 침윤 또는 혈관신생 억제제
KR101123130B1 (ko) * 2008-03-17 2012-03-30 연세대학교 산학협력단 Ｐｔｋ７ 단백질의 기능 저해를 통한 세포의 이동, 침윤 또는 혈관신생 억제제
WO2011004028A2 (en) 2009-07-10 2011-01-13 Innate Pharma Tlr3 binding agents
US8394922B2 (en) * 2009-08-03 2013-03-12 Medarex, Inc. Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
EP2380909A1 (en) * 2010-04-26 2011-10-26 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. PTK-7 protein involved in breast cancer
US9290499B2 (en) 2010-05-19 2016-03-22 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
SA112330278B1 (ar) * 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
US8852599B2 (en) 2011-05-26 2014-10-07 Bristol-Myers Squibb Company Immunoconjugates, compositions for making them, and methods of making and use
CN103958510B (zh) 2011-10-03 2016-10-19 北卡罗来纳大学教堂山分校 用于治疗癌症的吡咯并嘧啶化合物
MX350539B (es) 2012-02-13 2017-09-08 Bristol Myers Squibb Co Compuestos de enediino, conjugados de los mismos y sus usos y metodos.
RU2014145121A (ru) 2012-05-22 2016-07-10 Зэ Юниверсити Оф Норд Каролина Эт Чапел Хилл Пиримидиновые соединения для лечения злокачественной опухоли
MX361773B (es) 2012-05-31 2018-12-17 Innate Pharma Agentes de ligación a tlr3.
WO2014062774A1 (en) 2012-10-17 2014-04-24 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
EP2925752A4 (en) 2012-11-27 2016-06-01 Univ North Carolina PYRIMIDINE COMPOUNDS FOR CANCER TREATMENT
MX356698B (es) 2013-02-14 2018-06-11 Bristol Myers Squibb Co Compuestos de tubulisina, metodos para obtenerlos y uso.
ES2769876T3 (es) 2013-08-14 2020-06-29 Univ Rice William M Derivados de uncialamicina, métodos de síntesis y su uso como agentes antitumorales
AU2015244179A1 (en) * 2014-04-11 2016-11-03 The University Of North Carolina At Chapel Hill Mertk-specific pyrrolopyrimidine compounds
US9777070B2 (en) * 2014-04-30 2017-10-03 Pfizer Inc Anti-PTK7 antibody-drug conjugates
US10077287B2 (en) 2014-11-10 2018-09-18 Bristol-Myers Squibb Company Tubulysin analogs and methods of making and use
BR112017010094A2 (pt) 2014-11-21 2018-02-06 Bristol-Myers Squibb Company anticorpos compreendendo regiões constantes de cadeias pesadas modificadas
ES2747386T3 (es) 2015-01-14 2020-03-10 Bristol Myers Squibb Co Dímeros de benzodiacepina unidos por heteroarileno, conjugados de los mismos y métodos de preparación y uso
EA035412B1 (ru) * 2015-05-29 2020-06-10 Бристол-Майерс Сквибб Компани Антитела к ox40 и их применение
BR112018012524A2 (pt) 2015-12-21 2018-12-11 Bristol Myers Squibb Co anticorpos variantes para conjugação sítio-específica
MX378572B (es) 2016-01-22 2025-03-11 Merck Sharp & Dohme Llc Anticuerpos anti-factor de la coagulacion xi.
US10709708B2 (en) 2016-03-17 2020-07-14 The University Of North Carolina At Chapel Hill Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor
WO2017196598A1 (en) 2016-05-10 2017-11-16 Bristol-Myers Squibb Company Antibody-drug conjugates of tubulysin analogs with enhanced stability
KR102379580B1 (ko) 2016-06-14 2022-03-29 머크 샤프 앤드 돔 코포레이션 항응고 인자 xi 항체
US10287291B2 (en) 2016-08-19 2019-05-14 Bristol-Myers Squibb Company Seco-cyclopropapyrroloindole compounds, antibody-drug conjugates thereof, and methods of making and use
US10398783B2 (en) 2016-10-20 2019-09-03 Bristol-Myers Squibb Company Antiproliferative compounds and conjugates made therefrom
CN110352068A (zh) 2016-12-02 2019-10-18 南加利福尼亚大学 合成的免疫受体及其使用方法
EP4098662A1 (en) 2017-05-25 2022-12-07 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
US10457681B2 (en) 2017-08-16 2019-10-29 Bristol_Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor
US10494370B2 (en) 2017-08-16 2019-12-03 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor
US10508115B2 (en) 2017-08-16 2019-12-17 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor
US10487084B2 (en) 2017-08-16 2019-11-26 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor
US10472361B2 (en) 2017-08-16 2019-11-12 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor
WO2019209811A1 (en) 2018-04-24 2019-10-31 Bristol-Myers Squibb Company Macrocyclic toll-like receptor 7 (tlr7) agonists
IL312163B2 (en) 2018-05-29 2025-04-01 Bristol Myers Squibb Co Modified atomic groups that lend themselves to use in prodrugs and conjugates and methods for use and preparation
US11554120B2 (en) 2018-08-03 2023-01-17 Bristol-Myers Squibb Company 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor
CA3118830A1 (en) * 2018-11-07 2020-05-14 Crispr Therapeutics Ag Anti-ptk7 immune cell cancer therapy
EP3887397A1 (en) 2018-11-28 2021-10-06 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
KR20210098488A (ko) 2018-11-30 2021-08-10 브리스톨-마이어스 스큅 컴퍼니 글루타민-함유 경쇄 c-말단 연장부를 포함하는 항체, 그의 접합체, 및 방법 및 용도
EP3894443A2 (en) 2018-12-12 2021-10-20 Bristol-Myers Squibb Company Antibodies modified for transglutaminase conjugation, conjugates thereof, and methods and uses
KR102236127B1 (ko) 2019-08-08 2021-04-07 주식회사 하울바이오 티로시나아제를 억제하는 항-티로시나아제 항체 및 이의 용도
US20240377413A1 (en) 2019-09-16 2024-11-14 Bristol-Myers Squibb Company Dual capture method for analysis of antibody-drug conjugates
AR122014A1 (es) * 2020-05-06 2022-08-03 Crispr Therapeutics Ag Receptor de antígenos quimérico enmascarado específico para la proteína tirosina cinasa de tipo 7 (ptk7) y células inmunitarias que expresan el mismo
WO2022015113A1 (ko) * 2020-07-16 2022-01-20 연세대학교 산학협력단 Ptk7에 특이적으로 결합하는 항체 및 이의 용도
CN115894696A (zh) * 2021-08-18 2023-04-04 和迈生物科技有限公司 抗ptk7单域抗体及其应用
CN114213541B (zh) * 2021-12-20 2022-12-30 南京诺唯赞生物科技股份有限公司 一种全能核酸酶的单克隆抗体及其制备方法
EP4496592A1 (en) 2022-03-23 2025-01-29 Synaffix B.V. Antibody-conjugates for targeting of tumours expressing ptk7
KR20250012620A (ko) 2022-05-19 2025-01-24 마이틱 테라퓨틱스, 인크. Ph 의존적으로 결합하는 ptk7-결합 단백질 및 이의 용도
GB202209196D0 (en) * 2022-06-22 2022-08-10 Almac Discovery Ltd Bi-specific antigen binding molecules
CN119604535A (zh) * 2022-08-19 2025-03-11 四川科伦博泰生物医药股份有限公司 Ptk7结合蛋白及其用途
WO2024054030A1 (ko) * 2022-09-06 2024-03-14 연세대학교 산학협력단 항-ptk7 항체 및 이의 용도
WO2024080325A1 (ja) * 2022-10-14 2024-04-18 Jsr株式会社 抗体及びその使用
WO2024193679A1 (en) * 2023-03-23 2024-09-26 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Antibodies and uses thereof
CN118852442A (zh) * 2023-04-26 2024-10-29 上海麦科思生物医药有限公司 抗ptk7抗体及其用途
WO2025117639A1 (en) * 2023-11-27 2025-06-05 Profoundbio Us Co. Antibodies and methods for ptk7 detection

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4708930A (en) * 1984-11-09 1987-11-24 Coulter Corporation Monoclonal antibody to a human carcinoma tumor associated antigen
WO1996037610A2 (en) * 1995-05-25 1996-11-28 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Cck-4, a receptor tyrosine kinase, and methods for diagnosis and treatment of cck-4 signal transduction disorders
WO1997012862A1 (en) 1995-10-03 1997-04-10 The Scripps Research Institute Cbi analogs of cc-1065 and the duocarmycins
AU6887698A (en) 1997-04-08 1998-10-30 Sugen, Inc. Study and treatment of diseases related to specific cellular functions of receptor protein tyrosine kinases
EP0983248B1 (en) 1997-05-22 2004-07-14 The Scripps Research Institute Analogs of duocarmycin and cc-1065
ATE384744T1 (de) 1999-07-29 2008-02-15 Medarex Inc Menschliche antikörper gegen her2/neu
JP2005503760A (ja) 2001-01-24 2005-02-10 プロテイン デザイン ラブス， インコーポレイテッド 乳癌の診断方法、組成物および乳癌のモジュレーターのスクリーニング方法
WO2002086443A2 (en) 2001-04-18 2002-10-31 Protein Design Labs, Inc Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
AU2002303929B9 (en) 2001-05-31 2007-01-25 E. R. Squibb & Sons, L.L.C. Cytotoxins, prodrugs, linkers and stabilizers useful therefor
GB0114033D0 (en) 2001-06-09 2001-08-01 Innovata Biomed Ltd Process
CA2450316A1 (en) 2001-06-11 2002-12-19 Medarex, Inc. Cd10-activated prodrug compounds
IL159225A0 (en) 2001-06-13 2004-06-01 Genmab As Human monoclonal antibodies to epidermal growth factor receptor (egfr)
US20040076955A1 (en) 2001-07-03 2004-04-22 Eos Biotechnology, Inc. Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer
CA2459308A1 (en) 2001-09-07 2003-03-20 Dale L. Boger Cbi analogues of cc-1065 and the duocarmycins
JP2003088388A (ja) 2001-09-14 2003-03-25 Herikkusu Kenkyusho:Kk 新規な全長ｃＤＮＡ
CA2459219A1 (en) 2001-09-17 2003-03-27 Protein Design Labs, Inc. Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer
WO2003031930A2 (en) 2001-10-09 2003-04-17 The Johns Hopkins University A phosphatase associated with metastasis
WO2003042661A2 (en) 2001-11-13 2003-05-22 Protein Design Labs, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
CA2471645A1 (en) 2002-01-03 2003-07-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Immunoconjugates useful for treatment of tumours
EP1461359B1 (fr) * 2002-01-18 2007-03-21 Pierre Fabre Medicament Anticorps anti-igf-ir et leurs applications
US20040197792A1 (en) 2002-07-15 2004-10-07 Sugen, Inc. Novel Kinases
GB0219776D0 (en) * 2002-08-24 2002-10-02 Oxford Glycosciences Uk Ltd A protein involved in carcinoma
EP1605044A4 (en) 2003-03-10 2006-12-06 Japan Science & Tech Agency MARKERS FOR DETECTING MESENCHYMAL STEM CELLS AND METHOD FOR IDENTIFYING MESENCHYMAL STEM CELLS USING THE MARKER
EP2003196A3 (en) 2003-06-09 2009-01-07 The Regents of the University of Michigan Compositions and methods for treating and diagnosing cancer
WO2005063987A1 (en) 2003-12-19 2005-07-14 Aveo Pharmaceuticals, Inc. Gp153: methods and compositions for treating cancer
WO2005117941A2 (en) 2004-04-29 2005-12-15 Genzyme Corporation Methods and compositions for the treatment of polycystic diseases
MXPA06013413A (es) 2004-05-19 2007-01-23 Medarex Inc Enlazadores quimicos y conjugados de los mismos.
US7691962B2 (en) 2004-05-19 2010-04-06 Medarex, Inc. Chemical linkers and conjugates thereof
JP2008504270A (ja) 2004-06-23 2008-02-14 ジェンザイム・コーポレイション 嚢胞性疾患を処置するための方法および組成物
WO2006110593A2 (en) 2005-04-07 2006-10-19 Macrogenics, Inc. Biological targets for the diagnosis, treatment and prevention of cancer
ES2416136T3 (es) 2005-09-26 2013-07-30 Medarex, Inc. Conjugados de anticuerpo-fármaco y su uso
CN101360761B (zh) 2005-12-08 2012-09-12 米德列斯公司 抗蛋白质酪氨酸激酶7（ptk7）的人单克隆抗体及其用途
EP2229187A2 (en) 2007-11-30 2010-09-22 Bristol-Myers Squibb Company Monoclonal antibody partner molecule conjugates directed to protein tyrosine kinase 7 (ptk7)
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos

Also Published As

Publication number Publication date
ME02002B (me) 2013-10-31
SG177194A1 (en) 2012-01-30
WO2007067730A3 (en) 2007-11-01
RS52804B (en) 2013-10-31
CN101360761A (zh) 2009-02-04
US8222375B2 (en) 2012-07-17
US9102738B2 (en) 2015-08-11
IL191788A0 (en) 2009-02-11
NZ569236A (en) 2012-06-29
EA017812B1 (ru) 2013-03-29
EP1957539B1 (en) 2013-04-17
EP1957539A2 (en) 2008-08-20
AU2006321841A1 (en) 2007-06-14
EA200801509A1 (ru) 2008-12-30
US20100034826A1 (en) 2010-02-11
AU2006321841B2 (en) 2012-08-30
PT1957539E (pt) 2013-06-25
US20120207764A1 (en) 2012-08-16
KR101373464B1 (ko) 2014-03-14
US20120219557A1 (en) 2012-08-30
DK1957539T3 (da) 2013-05-06
PL1957539T3 (pl) 2013-08-30
KR20080082660A (ko) 2008-09-11
ES2406063T3 (es) 2013-06-05
CN101360761B (zh) 2012-09-12
IL191788A (en) 2014-06-30
HK1121174A1 (en) 2009-04-17
JP2009518039A (ja) 2009-05-07
NZ594466A (en) 2012-08-31
BRPI0619582A2 (pt) 2012-12-11
CA2632552A1 (en) 2007-06-14
WO2007067730A2 (en) 2007-06-14
CA2632552C (en) 2015-02-03
JP5401639B2 (ja) 2014-01-29
AU2006321841C1 (en) 2013-01-24
US9505845B2 (en) 2016-11-29
SI1957539T1 (sl) 2013-05-31

Similar Documents

Publication Publication Date Title
NO20082559L (no) Humane monoklonale antistoffer mot protein tyrosin kinase 7 (PTK7) og fremgangsmater for anvendelse av anti-PTK7 antistoffer
NO20092285L (no) Humane, monoklonale antistoffer til BTLA og fremgangsmater for anvendelse
NO20080590L (no) Humane, monoklonale antistoffer mot programmert dodsligand (PD-L1)
NO20081987L (no) Humane, monoklonale antistoffer mot CD70
NO20083062L (no) Humane monoklonale antistoffer mot fukosyl-GM1 og fremgangsmater for anvendelse av anti-fukosyl-GM1
NO20083053L (no) Humane monoklonale antistoffer mot O8E
NO20064866L (no) IRTA-5 antistoffer og deres anvendelse
NO20091283L (no) Humane antistoffer som binder CXCR4 og anvendelser derav
NO20073797L (no) Humane monoklonale antistoffer mot prostata spesifikt membran antigen (PSMA)
CY1121648T1 (el) ΑΝΘΡΩΠΙΝΑ ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ ΠΡΟΣ ΠΡΟΓΡΑΜΜΑΤΙΣΜΕΝΟ ΘΑΝΑΤΟ l(PD-l) ΚΑΙ ΜΕΘΟΔΟΙ ΓΙΑ ΤΗΝ ΑΝΤΙΜΕΤΩΠΙΣΗ ΚΑΡΚΙΝΟΥ ΧΡΗΣΙΜΟΠΟΙΩΝΤΑΣ ANTI-PD-1 ΑΝΤΙΣΩΜΑΤΑ ΜΟΝΑ Ή ΣΕ ΣΥΝΔΥΑΣΜΟ ΜΕ ΑΛΛΕΣ ΑΝΟΣΟΘΕΡΑΠΕΥΤΙΚΕΣ
NO20080362L (no) CD19-antistoffer og deres anvendelser
EA200901436A1 (ru) Антигенсвязывающие белки, связывающие par-2
DE602005027258D1 (de) Humane monoklonale antikörper gegen hendra- und nipah-viren
MEP53308A (en) Novel peptides that bind to the erythropoietin receptor
EA201101516A1 (ru) Антитела, специфические для кадгерина-17
EA200801174A1 (ru) Антитела-миметики glp-2, полипептиды, композиции, способы и применения
FI20011664A7 (fi) Syöpäpesifiset oligoskkaridisekvenssit ja niiden käyttö
DE602005027399D1 (de) Für humane matriptase spezifische bindungsproteine
WO2008109533A3 (en) Human antibodies that bind multiple irta family proteins, and uses thereof
WO2006116192A3 (en) Irta-1 antibodies and their uses
EA200700990A1 (ru) Новые пептиды, которые связывают рецептор эритропоэтина
CY1116843T1 (el) Ανθρωπινα μονοκλωνικα αντισωματα προς συνδετη 1 προγραμματισμενου θανατου (pd-l1)
CY1114151T1 (el) Ανθρωπινα μονοκλωνικα αντισωματα ως προς την κιναση τυροσινης πρωτεϊνης 7 (ρτκ7) και η χρηση αυτων
CY1113958T1 (el) Ανθρωπινα μονοκλωνικα αντισωματα σε φουκοζυλ-gμ1 και μεθοδοι για τη χρηση αντι-φουκοζυλ-gμ1

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: MEDAREX LLC, US

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: E.R. SQUIBB & SONS, US

FC2A Withdrawal, rejection or dismissal of laid open patent application